WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that researchers will present a poster at IDWeek 2014 showing the preclinical activity of eravacycline, a novel tetracycline in late-stage clinical development, against several Gram-negative pathogens found in New York City—a city particularly plagued by multidrug-resistant (MDR) bacteria. The researchers concluded that eravacycline, which is presently being studied in Phase 3 trials for complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), demonstrated excellent in vitro activity against Gram-negative MDR strains of E. coli, Klebsiella pnuemoniae, Enterobacter spp., and Acinetobacter baumannii. IDWeek takes place from October 8 – 12 in Philadelphia at The Pennsylvania Convention Center.
Help employers find you! Check out all the jobs and post your resume.
